We previously reported using mouse-virulent Salmonella typhimurium hybrids expressing Salmonella typhi antigens as challenge organisms in vaccinated Swiss-Webster white mice to test the protective abilities of typhoid vaccines (1) (2) (3) (4) . This assay system has proven capable of demonstrating differences in effectiveness among various kinds of typhoid vaccines with respect to their ability to confer protection against death of the animals (2) (3) (4) and has provided evidence that the Salmonella somatic antigens are important in conferring this protection (1) . Although our earlier studies employed only nonliving vaccines administered intraperitoneally (i.p.), we have recently extended our use of this system to assay the protective capabilities of both living and nonliving vaccines administered either i.p. or orally (4) .
Of the various typhoid vaccines that we have examined, live S. typhi administered i.p. is the most effective in protecting the mice against death when challenged with an S. typhimurium hybrid expressing S. typhi antigens (4) . However, since our primary concern is with evaluating those vaccines against S. typhi that are suitable for human use, we are particularly interested in examining, in this system, the protective capabilities of presently used as well as potential human typhoid vaccines. We were, therefore, especially intrigued by the report of Kiefer et al. (7) that mice immunized i.p. with an Escherichia coli hybrid expressing the somatic antigens of S. typhi were significantly protected against death when challenged with an S. typhimurium hybrid expressing S. typhi antigens. Be- cause an E. coli hybrid of this type would seem most promising for use as a safe, live, oral human typhoid vaccine, we were interested in comparing the protection it would confer in our assay system, administered orally as well as i.p., with that conferred by live S. typhi. Also, we wished to see whether the addition of the S. typhi Vi antigen to this E. coli hybrid (by conjugal gene transfer) would enhance that protection. In the present paper we report the results of these studies.
MATERIALS AND METHODS
Bacterial strains. The derivation and description of the S. typhi Hfr strain, WR4000, used to generate the E. coli hybrids, F1061 and WR3078, have been reported previously (6) . The E. coli parent strain, F464 (serotype 08:K-:H-), and E. coli hybrid F1061 were provided by G. Schmidt. E. coli hybrid F1061 is the product of a mating between S. typhi Hfr WR4000 and E. coli F464, as described elsewhere (8) Orally administered doses were introduced into the stomach with a bent, 25-gauge, 2-inch needle with its point removed and its end smoothed off. All animals were challenged i.p., 5 weeks after immunization, with 2,500 organisms (0.5 ml) of S. typhimurium hybrid H42, as in our previous live immunization experiments (4) . Survivors were counted after 21 days.
Test for statistical significance. The results of assays were analyzed as RXC tables by using the usual chi-square criterion (9) .
RESULTS
Comparison of protection conferred by living organisms administered i.p. Our previous finding (4) that live S. typhi administered i.p. conferred, in this assay system, the most effective protection against death of the animals was confirmed. As shown in Table 1 , i.p. administration of live S. typhi Ty2 resulted in an 87.5% survival of the mice challenged with S. typhimurium hybrid H42, compared with a 62.5% survival among the group immunized i.p. with the live E. coli hybrid F1061. The E. coli hybrid WR3078, expressing the Vi antigen in addition to its S. typhi 9 and 12 somatic antigens, showed no improvement over E. coli hybrid F1061, with only 55% of the immunized mice surviving the challenge. The failure of Vi antigen addition to enhance the protection afforded by a hybrid expressing the S. typhi somatic antigens has been observed previously in studies using S. typhimurium hybrids (acetone killed) as vaccinating strains (1) .
We examined also in this experiment the E. b Protection conferred by all of these strains is significantly better (P < 0.005) than the control. coli parent strain, F464, from which the hybrids were derived. Although ranking lowest in the protection comparison, it surprisingly conferred significant protection with 42.5% of the i.p.-inoculated mice surviving challenge (Table 1) . Nevertheless, in several repeated experiments with the parental and hybrid strains, the 20% difference in survival percentage seen here between E. coli F464 and the hybrid F1061 was maintained consistently, confining the importance of the S. typhi somatic antigens in the protection observed in this system.
Comparison of protection conferred by living organisms administered orally. Since the potential value of a hybrid such as E. coli F1061 would be its suitability for use in humans as an oral vaccine, we were especially interested in observing its performance in our assay system when administered by the oral route. We had reported earlier (4) a 42% survival among mice orally immunized with 107 live S. typhi Ty2 and challenged with S. typhimurium hybrid H42. This figure is almost exactly what we obtained with 107 live S. typhi Ty2 administered orally in the present study (Table 2) . However, at that dose level with live, orally administered F1061, although protection was still significantly better (P < 0.01) than in the control group, only 32.5% of the inoculated mice survived challenge.
Previously, we did not use oral dose levels of live S. typhi Ty2 higher than 107 because a number of mice died at higher dosages, particularly at 109. However, since the E. coli hybrids can be used safely at 109, we used this dose of live S. typhi Ty2 as well to make the comparison. As shown in Table 2 , oral administration of 109 live S. typhi Ty2 raised the level of protection (percent survival) to 67.5%, and with an oral dose of 109 live E. coli hybrid F1061 the survival 91 VOL. 24, 1979 on October 18, 2017 by guest http://iai.asm.org/ Downloaded from figure rose to 47.5%. The E. coli hybrid expressing the Vi antigen, WR3078, again showed no improvement over F1061, with only 40% of the orally immunized (109 dose) mice surviving. Once again, at the 109 dose, the E. coli parent strain exhibited a significant (P < 0.01) level of protection, with 32.5% of the mice in that group surviving. DISCUSSION It is evident from these experiments that both oral and i.p. immunization of Swiss-Webster white mice with live E. coli hybrid F1061 confers significant protection against death from challenge with S. typhimurium hybrid H42. It is also evident, however, that the protection conferred by live E. coli F1061 is inferior to that conferred by live S. typhi Ty2, 62.5% versus 87.5% in the i.p.-immunized mice, and 47.5% versus 67.5% in the mice immunized orally. Furthermore, addition of the S. typhi Vi antigen to E. coli hybrid F1061 (creating E. coli hybrid WR3078) did not produce a hybrid with better protective capability than F1061, which expresses only the S. typhi somatic antigens 9 and 12. The failure of Vi antigen addition to enhance the protective capability of F1061 is not only similar to our earlier observations with acetone-killed S. typhimurium hybrids as vaccinating strains (1), but is also consistent with our previous findings with regard to the Vi antigen in that we have yet to discover any role for it in the protection conferred in this system (1) (2) (3) (4) . Although our comparisons of the protective capabilities of E. coli hybrid F1061 and its parent F464 consistently indicated the importance of the S. typhi somatic antigens expressed by the hybrid, it would appear, nevertheless, that a substantial percentage of the overall ability of F1061 to confer protection in this system derives from the parent strain, F464, itself. We do not have sufficient data on the protective capabilities of different E. coli strains in this system to make valid comparisons, but with at least one other strain tested (E. coli WR3991, expressing O antigen 102, no K antigen), we have not observed the protection levels seen with F464. Unfortunately, we have not been successful in attempts to transfer the S. typhi somatic antigens to WR3991 and thus have no data to indicate how other E. coli hybrids would compare with F1061. However, we would suspect that factors other than the specificity of the S. typhi somatic antigens would affect the protective capabilities of hybrids in this system.
Although there are, as yet, no data to establish that comparative protective capabilities of live typhoid vaccines against S. typhimurium hybrid H42 in our system would be reflected similarly in their effectiveness against S. typhi in humans, we are, of course, hopeful that such will eventually prove to be the case. Therefore, it seems reasonable to consider what our present results might possibly imply regarding the potential of E. coli hybrids such as F1061 for use as live, oral, human typhoid vaccines. Initially, our data suggest that an attenuated S. typhi strain, such as the galE mutant Ty2la proposed by Germanier and Furer (5), might be a more effective human immunizing agent than an E. coli hybrid. Frankly, we had hoped that the protective capability exhibited by F1061 would more closely approximate that of S. typhi than was the case in our present experiments. Furthermore, the sizable contribution of its E. coli parent strain, F464, to that protective capability raises the question as to whether a similar contribution could be expected in the human situation. On the other hand, the E. coli hybrid F1061 did confer a significant degree of protection in our system, and it does not have the undesirable potential for producing a systemic infection in vaccinated humans that an S. typhi mutant has, should back-mutation occur. Also, it must be acknowledged that we did not test, in the present experiments, an attenuated S. typhi strain to establish how closely it would approximate, in our system, the protective capabilities of the nonattenuated S. typhi Ty2 strain. In the final analysis, however, it is only with human subjects in actual field trials that a realistic evaluation of the merits of these vaccines can be accomplished to determine whether the protection conferred by them in our test system reflects their effectiveness as human immunizing agents.
